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A Ab bs st tr ra ac ct t
BRCA1 and BRCA2 germ-line mutations occur in a significant number of unselected ovarian cancer (OC) patients,
thus making a noticeable contribution to OC morbidity. It is of interest whether CHEK2, which is frequently
regarded as a third breast cancer specific gene, is also relevant to ovarian cancer pathogenesis. In this report
we analyzed the presence of CHEK2 1100delC founder mutation in 268 randomly recruited OC patients. The
mutation was identified in 2 women with OC (0.8%) as compared to 1/448 (0.2%) healthy middle-aged and
0/373 elderly tumour-free women. Taken together this result and the negative findings of two other published
reports on an association of CHEK2 with ovarian cancer indicate that there is no justification for intensive ovarian
cancer screening in CHEK2 1100delC carriers.
I In nt tr ro od du uc ct ti io on n
A close relationship between breast and ovarian
cancer risks has been recognized by physicians for 
a considerable period of time. Not surprisingly, both
“classical” breast cancer (BC) predisposing genes,
BRCA1 and  BRCA2, turned out to be strongly
associated not only with BC, but also with ovarian
cancer [1, 2]. The third BC-associated gene, CHEK2,
appeared to be relevant to ovarian cancer since it was
observed that 4/99 (4.0%) carriers of the inactive
1100delC allele were present among the index cases
from breast-ovarian cancer families as compared to
only 18/1620 (1.1%) CHEK2 heterozygotes in control
subjects [3]. While the role of CHEK2 in breast cancer
predisposition has subsequently been proven [4, 5],
there are only two published reports analyzing the
relevance of 1100delC to ovarian cancer risk. Baysal
et al. [6] found no CHEK2 inactivating alleles in 751
unselected ovarian cancer cases, but detected one
1100delC heterozygote (1.9%) among 52 familial OC
patients; 521 control subjects contained 3 carriers
(0.6%) of the defective allele. Szymanska-Pasternak et
al. [7] also failed to detect truncating CHEK2 variants
in 209 ovarian cancer patients, while 0.7% of 4000
control subjects had an inactive copy of this gene.
The distribution of the CHEK2 1100delC allele
shows wide geographical variation; therefore only 
a few countries in the world are suitable for case-
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CHEK2 1100delC variant. The CHEK2 1100delC
allele was recently shown to be relevant to the
incidence of breast cancer in Sankt Petersburg (Russia);
therefore we reasoned that this population would be
valuable in the evaluation of its frequency in ovarian
cancer patients residing in the same city [8].
M Ma at te er ri ia al ls s   a an nd d   m me et th ho od ds s
The study included 268 ovarian cancer patients
undergoing treatment in N.N. Petrov Institute of
Oncology (Sankt Petersburg, Russia). The relevant
characteristics of the cases are presented in Table 1.
The healthy control population has already been
described by Chekmariova et al. [8] and Buslov et al.
[9]; it included 448 middle-aged female donors and
373 elderly tumour-free women. CHEK2 1100delC
genotyping was performed by real-time allele-specific
PCR. Primers were TTG GAG TGC CCA AAA TCA GT
(specific for the wild-type allele), CTT GGA GTG CCC
AAA ATC AT (specific for the mutated allele) and CTG
ATC TAG CCT ACG TGT CT (common primer). The
PCR mix included approximately 50 ng genomic DNA,
1 unit heat-activated Taq DNA polymerase, 1
x PCR
buffer (pH 8.3), 1.5 mM MgCl2, 200 μM dNTP , 
0.5 μM each primer, and 0.5
x SYBR Green I in a final
volume of 10 μl. PCR amplification and product
detection were carried out using the iCycler iQ Real
Time Detection System (Bio-Rad) for 50 cycles (95°C
for 35 sec., 57°C for 30 sec., 72°C for 30 sec.) after
an initial activation of the polymerase at 95°C for 
8 min. For each batch of assays control wild-type and
mutation-positive DNA samples were included. The
specificity of the 120-bp PCR product was confirmed
by DNA melting curve analysis. All mutation-positive
cases as well as some randomly selected DNA
specimens were also subjected to conventional allele-
specific PCR (35 cycles in the same conditions) followed
by restriction fragment detection by polyacrylamide gel
electrophoresis.
R Re es su ul lt ts s
CHEK2 1100delC was identified in 2 (0.8%) out of
268 ovarian cancer patients. One of the 1100delC
mutation positive patients, who was 67-years-old,
presented with an early stage (T1N0M0) tumour that
had serous adenocarcinoma histology (grade 2). The
second patient was 66-years-old; the tumor was also
a serous adenocarcinoma (grade 1), but the stage of
disease was significantly more advanced (T3NxM1).
Neither of the affected females reported a family history
of breast or ovarian cancer. The BRCA1 5382insC
mutation, which appears to be the most frequent
mutation in unselected Russian ovarian cancer patients,
was analyzed in 266 patients. From the 266 women,
T Ta ab bl le e   1 1. .   Clinical characteristics of the ovarian carcinoma patients
G Gr ro ou up ps s N Nu um mb be er r ( (% %) )
A Ag ge e   ( (y ye ea ar rs s) )
≤40 34 12.7
41-60 160 59.7
≥61 74 27.6
M Me ea an n   a ag ge e: :   53.1 years
A Ag ge e   r ra an ng ge e: :   21-89 years
T T   s st ta at tu us s
T=1 44 16.4
T>1 211 78.7
Non-informative 13 4.9
N N   s st ta at tu us s
N=0 101 37.7
N=1 52 19.4
Nx 102 38.1
Non-informative 13 4.9
M M   s st ta at tu us s
M=0 174 64.9
M=1 55 20.5
Mx 22 8.2
Non-informative 13 4.9
T Tu um mo ou ur r   d di if ff fe er re en nt ti ia at ti io on n
Grade 1 35 13.1
Grade 2 73 27.2
Grade 3  160 59.7
H Hi is st to ol lo og gy y
Serous adenocarcinoma 235 87.7
Mucinous adenocarcinoma 8 3.0
Adenocarcinoma, unspecified 14 5.2
Other 10 3.7
Non-informative 1 0.4
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22 (8.3%) BRCA1 5382insC heterozygotes were
identified and there were no instances of a simultaneous
occurrence of CHEK2 1100delC and BRCA1
5382insC alleles.
CHEK2 1100delC mutation was detected in 1/448
(0.2%) healthy middle-aged females and in none of
373 elderly tumour-free women [8]. None of the
statistical tests demonstrated a significant difference,
although a formal trend to an association was revealed
when comparing the occurrence of CHEK2 1100delC
variant in ovarian cancer patients against elderly
controls (p=0.095).
D Di is sc cu us ss si io on n
The most studied and well recognized breast/ovarian
cancer genes, BRCA1 and BRCA2, show a distinct
distribution in breast and ovarian cancer patients. In
breast cancer, the probability of finding a BRCA1 or
BRCA2 mutation is increased when BC patients are
selected for young age of disease onset and/or a family
history and/or the presence of multiple primary tumours.
In contrast, the selection of patients using these
parameters is not justified in ovarian cancer patients:
randomly recruited OC usually show a high frequency
of BRCA mutations comparable to highly selected cases
of BC. Furthermore, the trend of a family history or young
age of disease onset is less evident in BRCA-associated
ovarian cancer compared to breast cancers [10, 11].
While BRCA germ-line mutations contribute to 
a significant proportion of ovarian cancer cases [10, 11],
it appears that the CHEK2 1100delC allele is not
associated to any extent with ovarian cancer risk [6, 7,
and the present study]. It is an interesting scientific
question as to why BRCA1 and  BRCA2, being
completely different genes [1, 12], predispose to both
breast and ovarian tumourigenesis, whereas CHEK2
appears only to alter the risk of BC. It also remains
unclear whether some rare cases of non-breast cancer
can be somehow triggered by the CHEK2 1100delC
allele, or its presence is absolutely neutral for the
tumours developing outside mammary glands. Our
data on the absence of the CHEK2 1100delC variant
in elderly tumour-free women suggest that this mutation
decreases the probability of achieving old age without
cancer. However, although we observed a significant
frequency of CHEK2 1100delC heterozygotes in Russian
breast cancer patients (2.1%), the occurrence of this
allele in the corresponding middle-aged control group
is also very low (0.2%). Thus, it is unclear whether
depletion of CHEK2 1100delC mutation carriers in
middle-aged and elderly controls takes place as a result
of an increased likelihood of there being a cancer-
predisposing role of this allele, or its low frequency in
the control groups is simply attributable to a chance.
Overall, the disease significance of CHEK2
1100delC is difficult to determine because of the low
population frequency, uneven geographical distribution
and low cancer penetrance. To resolve these issues will
require much larger population-based studies requiring
a significant number of cancer patients and tumour-
free controls in order to clarify whether organs other
than the breast are at risk in CHEK2 1100delC carriers.
Taken together with published data [6, 7], the present
study does not justify the need for intensive ovarian
cancer screening in females bearing the CHEK2
1100delC allele.
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F Fi ig g. .   1 1. . Detection of CHEK2 1100delC mutation by real-time allele-specific PCR. When normal DNA is subjected to PCR, the amplification
driven by the wild-type specific primer significantly exceeds that initiated by mutation-specific oligonucleotide (left). In the case of CHEK2
1100delC heterozygosity, both wild-type and mutation-specific curves cross their threshold of detection at approximately the same cycle (right)
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